Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 May;70(5):1507-12.
doi: 10.1093/jac/dku535. Epub 2015 Jan 3.

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

Slim Fourati  1 , Charlotte Charpentier  2 , Corinne Amiel  3 , Laurence Morand-Joubert  4 , Sandrine Reigadas  5 , Mary-Anne Trabaud  6 , Constance Delaugerre  7 , Florence Nicot  8 , Audrey Rodallec  9 , Anne Maillard  10 , Audrey Mirand  11 , Hélène Jeulin  12 , Brigitte Montès  13 , Francis Barin  14 , Dominique Bettinger  15 , Hélène Le Guillou-Guillemette  16 , Sophie Vallet  17 , Anne Signori-Schmuck  18 , Diane Descamps  2 , Vincent Calvez  1 , Philippe Flandre  1 , Anne-Genevieve Marcelin  19 ; ANRS AC11 Resistance Study Group
Collaborators, Affiliations
Free article
Observational Study

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

Slim Fourati et al. J Antimicrob Chemother. 2015 May.
Free article

Abstract

Objectives: The objectives of this study were to determine the prevalence and patterns of resistance to integrase strand transfer inhibitors (INSTIs) in patients experiencing virological failure on raltegravir-based ART and the impact on susceptibility to INSTIs (raltegravir, elvitegravir and dolutegravir).

Patients and methods: Data were collected from 502 treatment-experienced patients failing a raltegravir-containing regimen in a multicentre study. Reverse transcriptase, protease and integrase were sequenced at failure for each patient. INSTI resistance-associated mutations investigated were those included in the last ANRS genotypic algorithm (v23).

Results: Among the 502 patients, at failure, median baseline HIV-1 RNA (viral load) was 2.9 log10 copies/mL. Patients had been previously exposed to a median of five NRTIs, one NNRTI and three PIs. Seventy-one percent harboured HIV-1 subtype B and the most frequent non-B subtype was CRF02_AG (13.3%). The most frequent mutations observed were N155H/S (19.1%), Q148G/H/K/R (15.4%) and Y143C/G/H/R/S (6.7%). At failure, viruses were considered as fully susceptible to all INSTIs in 61.0% of cases, whilst 38.6% were considered as resistant to raltegravir, 34.9% to elvitegravir and 13.9% to dolutegravir. In the case of resistance to raltegravir, viruses were considered as susceptible to elvitegravir in 11% and to dolutegravir in 64% of cases. High HIV-1 viral load at failure (P < 0.001) and low genotypic sensitivity score of the associated treatment with raltegravir (P < 0.001) were associated with the presence of raltegravir-associated mutations at failure. Q148 mutations were selected more frequently in B subtypes versus non-B subtypes (P = 0.004).

Conclusions: This study shows that a high proportion of viruses remain susceptible to dolutegravir in the case of failure on a raltegravir-containing regimen.

Keywords: inhibitors; integrase; mutations; patterns.

PubMed Disclaimer

Publication types

MeSH terms